Why Kyverna Therapeutics Stock Is Sinking
Portfolio Pulse from Erica Kollmann
Kyverna Therapeutics (NASDAQ:KYTX) shares are falling after the company presented data on its lead CAR T-cell therapy candidate, KYV-101, at an industry symposium. The stock has dropped 35.5% to $9.32, continuing its decline since its IPO in February.
June 14, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kyverna Therapeutics shares are down 35.5% to $9.32 after presenting data on KYV-101 at an industry symposium. The stock has lost over 68% since its IPO in February.
The significant drop in Kyverna's stock price following the presentation of KYV-101 data indicates a negative market reaction. The stock has been on a downward trend since its IPO, and the high short interest suggests potential for further volatility.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100